002173 Innovative Medical Management
- 8.14
- +0.14+1.75%
Innovative Medical Management News
Express News | Kanglong Chemical and AstraZeneca China reach strategic cooperation
Hong Kong Stock Concept Tracking | New Advances in Brain-Computer Interface Technology! Neuralink begins recruiting a second patient (with concept stock)
Musk announced that after 100 days of successful surgery for the first patient involved in the brain-computer device implantation experiment at the beginning of the year, Neuralink (Neuralink) has officially begun recruiting a second patient to receive a brain-computer implantation.
Changes in A-shares | Shareholders plan to reduce holdings in Innovative Healthcare, falling more than 12% for 2 consecutive days
Gelonghui, May 13 | Innovative Healthcare (002173.SZ) fell 6% again, falling more than 12% for 2 consecutive days. Now it is 7.89 yuan, with a total market value of 3.55 billion yuan. According to the news, the shareholder Shanghai Yanheng Investment Management Partnership (Limited Partnership) plans to reduce the company's shares by no more than 8.6747 million shares, with a reduction ratio of no more than 1.93% of the company's total share capital. According to reports, the company announced plans to reduce its holdings 6 times in the past three years. In addition, the recently announced net loss for the first quarter was 2,977,900 yuan, an increase of 37.87% year-on-year.
Express News | Innovative healthcare: Shanghai Yanheng plans to reduce shareholding by no more than 1%
Brain-computer interface concept stocks fluctuated and fell. Guanhao Biotech fell more than 8%, Sanbo Neurology and Aibang Medical fell more than 6%, and Innovative Healthcare and Shengxun Co., Ltd. followed suit.
Brain-computer interface concept stocks fluctuated and fell. Guanhao Biotech fell more than 8%, Sanbo Neurology and Aibang Medical fell more than 6%, and Innovative Healthcare and Shengxun Co., Ltd. followed suit.
Innovative Healthcare (002173.SZ): Net loss of 2,977,900 yuan in the first quarter
On April 26, Ge Longhui | Innovative Healthcare (002173.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 201 million yuan, down 1.40 from the previous year; net profit attributable to shareholders of listed companies - RMB 2,977,900; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - RMB 2.7087 million; and basic earnings per share - 0.0067 yuan.
Xinyi Biotech recently announced that it has received an investment of 100 million yuan from the Beijing Pharmaceutical Fund. Xinyi Biotech's current support from the Beijing Pharmaceutical Fund will accelerate the company's clinical registration of digit
Xinyi Biotech recently announced that it has received an investment of 100 million yuan from the Beijing Pharmaceutical Fund. Xinyi Biotech's current support from the Beijing Pharmaceutical Fund will accelerate the company's clinical registration of digital PCR and molecular POCT series reagent products. According to information, the Beijing Medical and Health Industry Investment Fund is a government investment fund in the medical and health industry established by Beijing at the end of 2023 that focuses on key industries such as innovative drugs and innovative medical devices, as well as emerging industries such as cell and gene therapy and digital medicine.
Express News | Beijing: Support the establishment of a training center for the application of innovative devices such as medical robots to accelerate the promotion and use of innovative medical devices
Innovative Healthcare (002173.SZ): Net loss of 34.2877 million yuan in 2023
On April 12, Ge Longhui (002173.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 806 million yuan, an increase of 13.51% over the previous year; net profit attributable to shareholders of listed companies was -34,287,700 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -280.26 million yuan; and basic earnings per share -0.08 yuan.
Express News | West China Hospital of Sichuan University signed a strategic cooperation framework agreement with iFLY Healthcare and Huawei to focus on the field of hospital artificial intelligence
Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review
Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colectin Biotechnology Co., Ltd. (hereinafter referred to as “colevipid”), a holding subsidiary of the company, received the “Jiangxi Province Class II Medical Device Innovative Product Registration Review Results Form” issued by the Jiangxi Drug Administration. The “Leakage Monitor”, a product independently developed by Colectin, was approved for the registration review of Class II medical device innovation products in Jiangxi Province.
Express News | Sano Healthcare: The subsidiary Sano Shenchang self-inflating intracranial drug-coated stent system passed a special review process for innovative medical devices
Aibo Healthcare (688050.SH): Product passed a special review process for innovative medical devices
Gelonghui, April 2 | Aibo Medical (688050.SH) announced that the company's “artificial lens” recently passed the Special Examination Procedure for Innovative Medical Devices by the Medical Device Technology Review Center of the State Drug Administration (Innovation Review Acceptance Number: CQTS2400048). This product is an artificial lens with the effect of extending depth of field. While providing farsightedness comparable to that of ordinary single-focus intraocular lenses, patients can benefit from useful medium- and near-vision. Currently, all domestic depth-of-field intraocular lens products rely on imports. The extended depth of field intraocular lens products developed by the company is based on many innovations
Express News | China has approved 259 innovative medical devices
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Concept Nuggets | China's brain-computer interface has achieved technological breakthroughs. Which companies are worth deploying?
Great potential for development
Express News | 32 funds were liquidated during the year, and today 7 funds were centrally issued liquidation reminder announcements
The idea controls the mouse, a new breakthrough in brain-computer interface! Musk's grand ambitions are not far off
Brain-computer interface+AI, full of buffs!
A-share changes丨Musk reveals new developments, the brain-computer interface concept is active, innovative medical care rises and falls
Gelonghui, Feb. 21 | The A-share brain-computer interface concept was active at the beginning of the market. Boji Pharmaceuticals rose more than 14%, Sanbo Neurology rose more than 13%, innovative medicine rose or stopped, and Guanhao Biotech, Nanjing Panda, and Aibang Medical were ahead of the curve. According to the news, Musk revealed during a Spaces event on the social media platform X that the first human subject from the brain-computer interface company Neuralink “appears to have fully recovered and can move the mouse on the computer screen using only his mind.”
Express News | 61 innovative medical devices were approved for sale last year, another record high
Analysis
Price Target
No Data
